Targets for use in diagnosis, prognosis and therapy of breast cancer
The invention is directed to methods of diagnosing breast cancer, susceptibility to breast cancer, nodal metastasis of a breast cancer and screening for breast cancer in an individual in need thereof comprising detecting the presence of a loss of heterozygosity/allelic imbalance (LOH/AI) at one or more specific loci (markers) in the genome of the individual, wherein the presence of the LOH/AI at the one or more specific loci in the genome of the individual is indicative of a diagnosis of breast cancer in the individual.
1. A method of detecting increased likelihood of nodal metastasis of a breast tumor in a human subject in need thereof comprising detecting an increase in a loss of heterozygosity (LOH) or allelic imbalance (AI) at the following loci: D7S821, D10S677, D15S128, D16S3401, and D17S2193 in breast tumor stroma of the subject, wherein the increase of LOH or AI at the loci D7S821, D10S677, D15S128, D16S3401, and D17S2193 in the breast tumor stroma indicates increased likelihood of nodal metastasis of the breast tumor in the subject.
2. The method of claim 1 , wherein the subject has sporadic breast cancer.
3. The method of claim 1 , wherein the LOH or AI is detected by performing polymerase chain reaction (PCR) on DNA obtained from the breast tumor stroma.
4. The method of claim 3 , wherein the LOH or AI is detected by PCR followed by gentoyping.
5. The method of claim 3 , further comprising detecting a mutation of the TP53 gene, wherein the mutation of the TP53 gene is detected
by performing PCR amplification of exons 4 to 9 of the TP53 gene followed by denaturing gradient gel electrophoresis.
6. A method of diagnosing detecting increased likelihood of breast cancer in a human subject in need thereof comprising detecting an increase in a loss of heterozygosity (LOH) or allelic imbalance (AI) at the following loci D7S821, D10S677, D15S128, D16S3401, and D17S2193 in breast tumor stroma of the subject, wherein the increase of LOH or AI at the loci D7S821, D10S677, D15S128, D16S3401, and D17S2193 in the breast tumor stroma indicates increased likelihood a diagnosis of breast cancer in the subject.
7. The method of claim 6 , wherein the subject has sporadic breast cancer.
8. The method of claim 6 , further comprising detecting a mutation of the TP53 gene in breast tumor stroma of the subject.
9. The method of claim 8 , wherein the mutation of the TP53 gene or the LOH or AI is detected by performing polymerase chain reaction (PCR) on DNA obtained from the breast tumor stroma.
10. The method of claim 6 , wherein the LOH or AI is detected by performing polymerase chain reaction PCR on DNA obtained from the breast tumor stroma.
11. The method of claim 9 , wherein the mutation of the TP53 gene is detected by performing PCR amplification of exons 4 to 9 of the TP53 gene followed by denaturing gradient gel electrophoresis.
12. The method of claim 10 , wherein the LOH or AI is detected by PCR followed by genotyping.
13. The method of claim 1 , further comprising detecting a mutation of the TP53 gene in breast tumor stroma of the subject.